China Capex To Depreciation vs Free Cash Flow Yield Analysis
CPHI Stock | USD 0.20 0.01 4.76% |
China Pharma financial indicator trend analysis is way more than just evaluating China Pharma Holdings prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether China Pharma Holdings is a good investment. Please check the relationship between China Pharma Capex To Depreciation and its Free Cash Flow Yield accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Capex To Depreciation vs Free Cash Flow Yield
Capex To Depreciation vs Free Cash Flow Yield Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of China Pharma Holdings Capex To Depreciation account and Free Cash Flow Yield. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between China Pharma's Capex To Depreciation and Free Cash Flow Yield is -0.08. Overlapping area represents the amount of variation of Capex To Depreciation that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of China Pharma Holdings, assuming nothing else is changed. The correlation between historical values of China Pharma's Capex To Depreciation and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Depreciation of China Pharma Holdings are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Capex To Depreciation i.e., China Pharma's Capex To Depreciation and Free Cash Flow Yield go up and down completely randomly.
Correlation Coefficient | -0.08 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Capex To Depreciation
The ratio of a company's capital expenditures to its depreciation expenses, indicating how much the company is investing in physical assets relative to the aging of existing assets.Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Most indicators from China Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into China Pharma Holdings current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. As of now, China Pharma's Enterprise Value Over EBITDA is increasing as compared to previous years. The China Pharma's current Enterprise Value Multiple is estimated to increase to 654.35, while Selling General Administrative is projected to decrease to under 1.4 M.
China Pharma fundamental ratios Correlations
Click cells to compare fundamentals
China Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
China Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 22.2M | 21.1M | 22.6M | 17.8M | 16.5M | 15.6M | |
Short Long Term Debt Total | 4.6M | 7.4M | 12.5M | 8.8M | 4.6M | 7.4M | |
Other Current Liab | 5.8M | 2.9M | 1.3M | 1.7M | 1.6M | 1.6M | |
Total Current Liabilities | 10.0M | 11.4M | 10.5M | 12.7M | 6.8M | 9.2M | |
Total Stockholder Equity | 9.2M | 8.0M | 6.0M | 4.3M | 7.5M | 7.1M | |
Property Plant And Equipment Net | 16.0M | 15.2M | 13.0M | 9.6M | 6.8M | 13.2M | |
Net Debt | 3.5M | 6.5M | 7.6M | 6.7M | 3.2M | 4.3M | |
Retained Earnings | (26.0M) | (28.8M) | (32.2M) | (36.2M) | (39.3M) | (37.3M) | |
Accounts Payable | 1.4M | 1.2M | 926.7K | 667.1K | 966.4K | 1.7M | |
Cash | 1.1M | 957.7K | 4.9M | 2.0M | 1.4M | 2.8M | |
Non Current Assets Total | 16.7M | 15.8M | 13.6M | 11.8M | 10.5M | 9.9M | |
Cash And Short Term Investments | 1.1M | 957.7K | 4.9M | 2.0M | 1.4M | 2.8M | |
Net Receivables | 727.8K | 583.3K | 835.4K | 464.5K | 662.4K | 629.3K | |
Liabilities And Stockholders Equity | 22.2M | 21.1M | 22.6M | 17.8M | 16.5M | 15.6M | |
Non Current Liabilities Total | 3.0M | 1.7M | 6.1M | 754.7K | 2.2M | 3.5M | |
Total Liab | 13.0M | 13.1M | 16.6M | 13.5M | 9.0M | 12.7M | |
Property Plant And Equipment Gross | 16.0M | 15.2M | 41.1M | 38.0M | 37.2M | 39.1M | |
Total Current Assets | 5.6M | 5.3M | 9.1M | 6.0M | 6.0M | 5.7M | |
Accumulated Other Comprehensive Income | 11.6M | 12.3M | 12.6M | 11.6M | 11.5M | 9.9M | |
Short Term Debt | 2.4M | 6.5M | 7.2M | 8.8M | 3.2M | 4.4M | |
Current Deferred Revenue | 505.4K | 719.8K | 210.0K | 520.3K | 90.5K | 86.0K | |
Non Currrent Assets Other | (16.7M) | (15.8M) | (13.6M) | (11.8M) | (397.7K) | (417.6K) | |
Inventory | 3.6M | 3.7M | 3.3M | 2.9M | 3.7M | 3.5M | |
Other Current Assets | 187.4K | 75.9K | 59.3K | 522.3K | 178.2K | 169.3K | |
Intangible Assets | 609.4K | 613.8K | 589.6K | 2.2M | 3.7M | 3.4M | |
Other Liab | 764.4K | 753.4K | 805.6K | 824.4K | 948.1K | 718.4K | |
Property Plant Equipment | 19.3M | 16.3M | 15.6M | 13.4M | 15.4M | 17.9M | |
Net Tangible Assets | 29.9M | 9.0M | 7.8M | 5.9M | 5.3M | 5.0M | |
Long Term Debt | 2.2M | 904.2K | 5.3M | 1.4M | 1.3M | 2.5M | |
Retained Earnings Total Equity | 5.5M | (5.3M) | (26.0M) | (28.8M) | (26.0M) | (24.7M) | |
Short Term Investments | 45.8K | 53.7K | 91.4K | 13.8K | 65.9K | 80.7K | |
Deferred Long Term Liab | 738.2K | 764.4K | 753.4K | 805.6K | 926.4K | 788.0K | |
Short Long Term Debt | 2.3M | 6.5M | 7.1M | 8.7M | 3.1M | 4.3M |
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in China Pharma Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.